Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.3% in the third quarter, HoldingsChannel.com reports. The fund owned 301,508 shares of the biopharmaceutical company’s stock after purchasing an additional 3,866 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Regeneron Pharmaceuticals were worth $316,957,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of REGN. Sachetta LLC grew its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares in the last quarter. Stephens Consulting LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at approximately $26,000. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at approximately $28,000. Lynx Investment Advisory purchased a new position in Regeneron Pharmaceuticals during the second quarter worth approximately $33,000. Finally, Family Firm Inc. purchased a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 7.48% of the stock is owned by company insiders.

Regeneron Pharmaceuticals Stock Down 0.3 %

Shares of NASDAQ:REGN opened at $825.68 on Tuesday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $784.96 and a fifty-two week high of $1,211.20. The stock has a market cap of $90.73 billion, a price-to-earnings ratio of 20.43, a price-to-earnings-growth ratio of 3.13 and a beta of 0.15. The firm’s 50 day moving average price is $1,014.52 and its 200 day moving average price is $1,037.74.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the stock. Truist Financial lowered their price target on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Evercore ISI cut their price target on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, Wells Fargo & Company reduced their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, three have given a hold rating and eighteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,107.25.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.